Modulation of γ-Secretase Reduces β-Amyloid Deposition in a Transgenic Mouse Model of Alzheimer's Disease

Neuron

Volumn 67, Issue 5, 2010, Pages 769-780

  Kounnas, Maria Z ^d   Danks, Anne M ^d   Cheng, Soan ^d   Tyree, Curtis ^d   Ackerman, Elizabeth ^d   Zhang, Xulun ^a   Ahn, Kwangwook ^b   Nguyen, Phuong ^d   Comer, Dan ^d   Mao, Long ^d   Yu, Chengzhi ^d   Pleynet, David ^d   Digregorio, Paul J ^d   Velicelebi, Gonul ^d   Stauderman, Kenneth A ^d   Comer, William T ^d   Mobley, William C ^e   Li, Yue Ming ^b   Sisodia, Sangram S ^a   Tanzi, Rudolph E ^c   Wagner, Steven L ^d   more..

^a UNIVERSITY OF CHICAGO   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d TorreyPines Therapeutics Inc   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; GAMMA SECRETASE; NOTCH RECEPTOR; 4-(2-((1R)-1-(((4-CHLOROPHENYL)SULFONYL)-2,5-DIFLUOROANILINO)ETHYL)-5-FLUOROPHENYL)BUTANOIC ACID; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA-PROTEIN (1-42); AMYLOID PRECURSOR PROTEIN; ANTIBODY; BUTYRIC ACID DERIVATIVE; CADHERIN; ENZYME INHIBITOR; HALOGENATED HYDROCARBON; PEPTIDE FRAGMENT; PRESENILIN 1; PSEN1 PROTEIN, HUMAN; SECRETASE;

AFFINITY CHROMATOGRAPHY; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CELL DIFFERENTIATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; EMBRYO; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE OVEREXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MALE; MOUSE; NEUROFIBRILLARY TANGLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DOMAIN; RAT; SENILE PLAQUE; TRANSGENE; ANALYSIS OF VARIANCE; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMISTRY; CRICETULUS; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HAMSTER; IMMUNOLOGY; MASS SPECTROMETRY; METABOLISM; PROCEDURES; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES; BUTYRIC ACIDS; CADHERINS; CELLS, CULTURED; CRICETINAE; CRICETULUS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE EXPRESSION REGULATION; HUMANS; HYDROCARBONS, HALOGENATED; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PRESENILIN-1; RATS; RECEPTORS, NOTCH; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TRANSFECTION; AMYLOID BETA-PEPTIDES; BUTYRATES;

EID: 77956311201     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuron.2010.08.018     Document Type: Article

References (40)

1. Anderson J.J., Holtz G., Baskin P.P., Turner M., Rowe B.R., Wang B., Kounnas M.Z., Lamb B.T., Barten D., Felsenstein K., et al. Reductions in β-amyloid concentrations in vivo by the γ-secretase inhibitors BMS-289948 and BMS-299897. Biochem. Pharmacol. 2005, 69:689-698.
2. Best J.D., Smith D.W., Reilly M.A., O'Donnell R., Lewis H.D., Ellis S., Wilkie N., Rosahl T.W., Laroque P.A., Boussiquet-Leroux C., et al. The novel γ secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse. J. Pharmacol. Exp. Ther. 2007, 320:552-558.
3. Campbell S.K., Switzer R.C., Martin T.L. Alzheimer's plaques and tangles: a controlled and enhanced silver staining method. Soc. Neurosci. Abstr. 1987, 13:189.9.
4. Cao X., Sudof T.C. A transcriptionally active complex of APP with Fe65 and histone acetyl-transferase Tip60. Science 2001, 293:115-120.
5. Cirrito J.R., May P.C., O'Dell M.A., Taylor J.W., Parsadanian M., Cramer J.W., Audia J.E., Nissen J.S., Bales K.R., Paul S.M., et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J. Neurosci. 2003, 23:8844-8853.
6. De Strooper B., Annart W., Cupers P., Saftig P., Craessarts K., Mumm J.S., Schroeter E.H., Schrijvers V., Wolfe M.S., Ray W.I., et al. A presenilin-1-dependent γ-secretase-like protease mediates release of notch intracellular domain. Nature 1999, 358:518-522.
7. Dovey H.F., John V., Anderson J.P., Chen L.Z., de Saint Andrieu P., Fang L.Y., Freedman S.B., Folmer B., Goldbach E., Holsztynska E.J., et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J. Neurochem. 2001, 76:173-181.
8. Fleisher A.S., Raman R., Siemers E.R., Becerra L., Clark C.M., Dean R.A., Farlow M.R., Galvin J.E., Peskind E.R., Quinn J.F., et al. Phase 2 safety trial targeting amyloid β production with a γ-secretase inhibitor in Alzheimer disease. Arch. Neurol. 2008, 65:1031-1038.
9. Fraering P.C., LaVoie M.J., Ye W., Ostaszewski B.L., Kimberly W.T., Selkoe D.J., Wolfe M.S. Detergent-dependent dissociation of active gamma-secretase reveals an interaction between Pen-2 and PS1-NTF and offers a model for subunit organization within the complex. Biochemistry 2004, 43:323-333.
10. Ghaemmaghami S., May B.C.H., Renslo A.R., Prusiner S.B. Discovery of 2-aminothiazoles as potent antiprion compounds. J. Virol. 2010, 84:3408-3412.
11. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
12. Hyde L.A., McHugh N.A., Chen J., Zhang Q., Manfra D., Nomeir A.A., Josien H., Bara T., Clader J.W., Zhang L., et al. Studies to investigate the in vivo therapeutic window of the γ-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse. J. Pharmacol. Exp. Ther. 2006, 319:1133-1143.
13. Imbimbo B.P., Del Giudice E., Colavito D., D'Arrigo A., Dalle Carbonare M., Villetti G., Facchinetti F., Volta R., Pietrini V., Baroc M.F., et al. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel γ-secretase modulator, reduces brain β-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. J. Pharmacol. Exp. Ther. 2007, 323:822-830.
14. Kim S.-H., Sisodia S.S. A sequence within the first transmembrane domain of PEN-2 is critical for PEN-2-mediated endoproteolysis of presenilin 1. J. Biol. Chem. 2005, 280:1992-2001.
15. Kopan R., Goate A. A common enzyme connects notch signaling and Alzheimer's disease. Genes Dev. 2000, 14:2799-2806.
16. Kopan R., Ilagan M.X. Gamma-secretase: Proteosome of the membrane?. Nat. Rev. Mol. Cell Biol. 2004, 5:486-488.
17. Kreft A.F., Martone R., Porte A. Recent advances in the identification of γ-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease. J. Med. Chem. 2009, 52:6169-6188.
18. Kukar T.L., Ladd T.B., Bann M.A., Fraering P.C., Narlawar R., Maharvi G.M., Healy B., Chapman R., Welzel A.T., Price R.W., et al. Substrate-targeting γ-secretase modulators. Nature 2008, 453:925-929.
19. LaVoie M.J., Selkoe D.J. The Notch ligands, Jagged and Delta, are sequentially processed by α-secretase and presenilin/γ-secretase and release signaling fragments. J. Biol. Chem. 2003, 278:34427-34437.
20. Lewis H.D., Perez Revuelta B.I., Nadin A., Neduvelil J.G., Harrison T., Pollack S.J., Shearman M.S. Catalytic site-directed γ-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and β-APP cleavages. Biochemistry 2003, 42:7580-7586.
21. Li Y.M., Xu M., Lai M.T., Huang Q., Castro J.L., DiMuzio-Mower J., Harrison T., Lellis C., Nadin A., Neduvelil J.G., et al. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 2000, 405:689-694.
22. Marambaud P., Shioi J., Serban G., Sarner S., Georgakopoulos A., Nagy V., Baki L., Wen P., Efthimiopoulos S., Shao Z., et al. A presenilin-1/γ-secretase cleavage releases the e-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J. 2002, 21:1948-1956.
23. Martone R.L., Zhou H., Atchison K., Comery T., Xu J.Z., Huang X., Gong X., Jin M., Kreft A., Harrison B., et al. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein γ-secretase for the treatment of Alzheimer's disease. J. Pharmacol. Exp. Ther. 2009, 331:598-608.
24. Milano J., McKay J., Dagenais C., Foster-Brown L., Pognan F., Gadient R., Jacobs R.T., Zacco A., Greenberg B., Ciaccio P.J. Modulation of notch processing by γ-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol. Sci. 2004, 82:341-358.
25. Page R.M., Baumann K., Tomioka M., Pérez-Revuelta B.I., Fukumori A., Jacobsen H., Flohr A., Luebbers T., Ozmen L., Steiner H., Haass C. Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and γ-secretase modulation. J. Biol. Chem. 2008, 283:677-683.
26. Placanica L., Tarassishin L., Yang G., Peethumnongsin E., Kim S.-H., Zheng H., Sisodia S.S., Li Y.-M. Pen2 and presenilin-1 modulate the dynamic equilibrium of presenilin-1 and presenilin-2 γ-secretase complexes. J. Biol. Chem. 2009, 284:2967-2977.
27. Pissarnitski D. Advances in γ-secretase modulation. Curr. Opin. Drug Discov. Dev. 2007, 10:392-402.
28. Searfoss G.H., Jordan W.H., Calligaro D.O., Galbreath E.J., Schirtzinger L.M., Berridge B.R., Gao H., Higgins M.A., May P.C., Ryan T.P. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional γ-secretase inhibitor. J. Biol. Chem. 2003, 278:46107-46116.
29. Serneels L., Van Biervliet J., Craessaerts K., Dejaegere T., Horré K., Van Houtvin T., Esselmann H., Paul S., Schäfer M.K., Berezovska O., et al. gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science 2009, 324:639-642.
30. Shelton C.C., Zhu L., Chau D., Yang L., Wang R., Djaballah H., Zheng H., Li Y.-M. Modulation of γ-secretase specificity using small molecule allosteric inhibitors. Proc. Natl. Acad. Sci. USA 2009, 106:20228-20233.
31. Sisodia S.S., St George-Hyslop P.H. gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in?. Nat. Rev. Neurosci. 2002, 3:281-290.
32. Starrett, J.E., Jr., Gillman, K.W., and Olson, R.E. (2009). A alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production. U.S. Patent Application 2009/0111858 A1.
33. Tanzi R.E., Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005, 120:545-555.
34. Tian G., Sobotka-Briner C.D., Zysk J., Liu X., Birr C., Sylvester M.A., Edwards P.D., Scott C.D., Greenberg B.D. Linear non-competitive inhibition of solubilized human gamma-secretase by pepstatin A methylester, L685458, sulfonamides, and benzodiazepines. J. Biol. Chem. 2002, 277:31499-31505.
35. Tomita T. Secretase inhibitors and modulators for Alzheimer's disease treatment. Expert Rev. Neurother. 2009, 9:661-679.
36. Vassar R., Kovacs D.M., Yan R., Wong P.C. The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J. Neurosci. 2009, 29:12787-12794.
37. Wagner S.L., Munoz B. Modulation of amyloid β protein precursor processing as a means of retarding progression of Alzheimer's disease. J. Clin. Invest. 1999, 104:1329-1332.
38. Wakabayashi T., De Strooper B. Presenilins: Members of the γ-secretase quartets, but part time soloists too. J. Physiol. 2008, 23:194-204.
39. Weggen S., Eriksen J.L., Das P., Sagi S.A., Wang R., Pietrik C.U., Findlay K.A., Smith T.E., Murphy M.P., Butler T., et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001, 414:159-160.
40. Wong G.T., Manfra D., Poulet F.M., Zhang Q., Josien H., Bara T., Engstrom L., Pinzon-Ortiz M., Fine J.S., Lee H.-J., et al. Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibits β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem. 2004, 279:12876-12882.